Literature DB >> 6862586

Pharmacokinetics and metabolism of nifedipine.

K D Raemsch, J Sommer.   

Abstract

Nifedipine is almost completely absorbed from the gastrointestinal tract as shown by plasma levels after sublingual, oral, and rectal administration. Because of presystemic metabolism, the bioavailability is about 56% to 77%. After oral administration of 10 mg, the mean plasma concentration of nifedipine reaches maximum values of 160 +/- 49 micrograms/liter after 30 to 60 minutes. After 8 hours, the mean concentration drops to 3.4 +/- 1.2 micrograms/liter. After intravenous administration (0.015 mg/kg) biphasic elimination occurs, the half-life of the alpha-phase being about 13 minutes and of the beta-phase 1.26 +/- 0.55 hours in healthy volunteers. After oral administration of higher doses (40 mg) and after continuous infusion over 24 hours, a third phase with a half-life of about 8 hours can be seen. The apparent volume of distribution of the central compartment (Vce) is 0.294 +/- 0.1 l/kg, and the total body clearance amounts to 0.45 +/- 0.1 liter/hr . kg. Nifedipine is eliminated from the body by hepatic metabolism to the major metabolites 2,6-dimethyl-4-(2-nitrophenyl)-5-methoxycarbonyl-pyridine-3-carboxylic acid (M I) and the corresponding 2-hydroxymethyl-pyridinecarboxylic acid (M II). Methods for the quantitative detection of unchanged nifedipine in the presence of the pyridine analog in plasma (HPLC) and of the main metabolites in plasma and urine (GLC) have been developed. A simple semiquantitative method for detecting metabolites in urine (HPTLC) can be used to monitor patient compliance.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6862586     DOI: 10.1161/01.hyp.5.4_pt_2.ii18

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  34 in total

1.  An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine.

Authors:  T Edeki; A Johnston; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  Effect of Gastric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine.

Authors:  Ahmed M Nader; Sara K Quinney; Hala M Fadda; David R Foster
Journal:  AAPS J       Date:  2016-04-22       Impact factor: 4.009

4.  Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.

Authors:  D R Robertson; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

5.  Inter- and intra-subject variability of nitrendipine and the effects of food.

Authors:  J Lobo; D B Jack; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Factors affecting the pharmacokinetics of nifedipine.

Authors:  A G Renwick; J Le Vie; V F Challenor; D G Waller; B Gruchy; C F George
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Food and nifedipine pharmacokinetics.

Authors:  V F Challenor; D G Waller; B S Gruchy; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

8.  Dose response and length of action of nifedipine capsules and tablets in patients with essential hypertension: a randomised crossover study.

Authors:  F P Cappuccio; N D Markandu; F A Tucker; G A MacGregor
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

Review 10.  Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.

Authors:  P D Pearigen; N L Benowitz
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.